A retrospective chart review study investigated a DDI between CBD and mTOR inhibitors, such as everolimus and sirolimus, in a cohort of 25 patients with TSC (18 with everolimus, 7 with sirolimus) [44]. The gene discussed is MTOR; the disease is tuberous sclerosis.